Epigenetic attire in ovarian cancer: The Emperor's new clothes

Published on Sep 15, 2020in Cancer Research9.727
· DOI :10.1158/0008-5472.CAN-19-3837
Daniela Matei59
Estimated H-index: 59
(NU: Northwestern University),
Kenneth P. Nephew10
Estimated H-index: 10
(IU: Indiana University)
+ -1 AuthorsKenneth P. Nephew70
Estimated H-index: 70
(IU: Indiana University)
Ovarian cancer (OC) is an aggressive epithelial tumor that remains a major cause of cancer morbidity and mortality in women. Epigenetic alterations including DNA methylation and histone modifications are being characterized in OC and have been functionally linked to processes involved in tumor initiation, chemotherapy resistance, cancer stem cell survival, and tumor metastasis. The epigenetic traits of cancer cells and of associated tumor microenvironment components have been shown to promote an immunosuppressive tumor milieu. However, DNA methylation and histone modifications are reversible and therapies targeting the epigenome have been implicated in potential reinvigoration of the antitumor immunity. In this review, we provide an overview specifically of DNA methylation and histone modifications as "clothes of the ovarian cancer genome" in relationship to their functional effects and highlight recent developments in the field. We also address the clinical implications of therapeutic strategies to remove or alter specific articles of genomic "clothing" and restore normal cellular function. As the clothes of the genome continue to be deciphered, we envision that the epigenome will become an important therapeutic target for cancer.
📖 Papers frequently viewed together
2 Citations
30 Citations
31 Citations
#1Stephanie Gomez (GW: George Washington University)H-Index: 3
#2Tomasz Tabernacki (GW: George Washington University)H-Index: 1
Last. Katherine B. Chiappinelli (GW: George Washington University)H-Index: 16
view all 5 authors...
Abstract Cancer undergoes “immune editing” to evade destruction by cells of the host immune system including natural killer (NK) cells and cytotoxic T lymphocytes (CTLs). Current adoptive cellular immune therapies include CAR T cells and dendritic cell vaccines, strategies that have yet to show success for a wide range of tumors. Cancer resistance to immune therapy is driven by extrinsic factors and tumor cell intrinsic factors that contribute to immune evasion. These extrinsic factors include i...
18 CitationsSource
#1Wa Zhang (UNMC: University of Nebraska Medical Center)H-Index: 12
#2David Klinkebiel (UNMC: University of Nebraska Medical Center)H-Index: 16
Last. Adam R. Karpf (UNMC: University of Nebraska Medical Center)H-Index: 44
view all 9 authors...
A hallmark of human cancer is global DNA hypomethylation (GDHO), but the mechanisms accounting for this defect and its pathological consequences have not been investigated in human epithelial ovarian cancer (EOC). In EOC, GDHO was associated with advanced disease and reduced overall and disease-free survival. GDHO (+) EOC tumors displayed a proliferative gene expression signature, including FOXM1 and CCNE1 overexpression. Furthermore, DNA hypomethylation in these tumors was enriched within genom...
13 CitationsSource
#1Amit M. Oza (UHN: University Health Network)H-Index: 21
#2Ursula A. Matulonis (Harvard University)H-Index: 85
Last. Daniela Matei (NU: Northwestern University)H-Index: 59
view all 28 authors...
Purpose: Platinum resistance in ovarian cancer (OC) is associated with epigenetic modifications. Hypomethylating agents (HMAs) have been studied as carboplatin re-sensitizing agents in OC. This randomized phase 2 trial compared guadecitabine, a second generation HMA, and carboplatin (G+C) against second-line chemotherapy in women with measurable or detectable platinum-resistant OC. Experimental Design: Patients received either G+C (guadecitabine 30 mg/m2 SC once-daily for 5 days and carboplatin)...
24 CitationsSource
#1Sara Moufarrij (GW: George Washington University)H-Index: 3
#2Aneil Srivastava (GW: George Washington University)H-Index: 2
Last. Katherine B. Chiappinelli (GW: George Washington University)H-Index: 16
view all 14 authors...
Novel therapies are urgently needed for ovarian cancer, the deadliest gynecologic malignancy. Ovarian cancer has thus far been refractory to immunotherapies that stimulate the host immune system to recognize and kill cancer cells. This may be because of a suppressive tumor immune microenvironment and lack of recruitment and activation of immune cells that kill cancer cells. Our previous work showed that epigenetic drugs including DNA methyltransferase inhibitors and histone deacetylase 6 inhibit...
14 CitationsSource
#1Horacio Cardenas (NU: Northwestern University)H-Index: 18
#2Guanglong Jiang (IUPUI: Indiana University – Purdue University Indianapolis)H-Index: 14
Last. Daniela Matei (Veterans Health Administration)H-Index: 59
view all 10 authors...
Loss-of-function mutations of the breast cancer type 1 susceptibility protein (BRCA1) are associated with breast (BC) and ovarian cancer (OC). To identify gene signatures regulated by epigenetic mechanisms in OC cells carrying BRCA1 mutations, we assessed cellular responses to epigenome modifiers and performed genome-wide RNA- and chromatin immunoprecipitation-sequencing in isogenic OC cells UWB1.289 (carrying a BRCA1 mutation, BRCA1-null) and UWB1.289 transduced with wild-type BRCA1 (BRCA1+). I...
7 CitationsSource
#1Stephen Shang (UVA: University of Virginia)H-Index: 4
#2Jiekun Yang (UVA: University of Virginia)H-Index: 8
Last. Mazhar Adli (UVA: University of Virginia)H-Index: 29
view all 16 authors...
Chemoresistance is driven by unique regulatory networks in the genome that are distinct from those necessary for cancer development. Here, we investigate the contribution of enhancer elements to cisplatin resistance in ovarian cancers. Epigenome profiling of multiple cellular models of chemoresistance identified unique sets of distal enhancers, super-enhancers (SEs) and their gene targets that coordinate and maintain the transcriptional program of the platinum-resistant state in ovarian cancer. ...
17 CitationsSource
#1Meghan Travers (Johns Hopkins University)H-Index: 6
#2Stephen M. Brown (Johns Hopkins University)H-Index: 3
Last. Cynthia A. Zahnow (Johns Hopkins University)H-Index: 34
view all 11 authors...
Although ovarian cancer has a low incidence rate, it remains the most deadly gynecologic malignancy. Previous work has demonstrated that the DNMTi 5-Azacytidine (5AZA-C) activates type I interferon signaling to increase IFNγ + T cells and natural killer (NK) cells and reduce the percentage of macrophages in the tumor microenvironment. To improve the efficacy of epigenetic therapy, we hypothesized that the addition of α-difluoromethylornithine (DFMO), an ornithine decarboxylase inhibitor, may fur...
23 CitationsSource
#1Denarda Dangaj (Ludwig Institute for Cancer Research)H-Index: 10
#2Marine Bruand (Ludwig Institute for Cancer Research)H-Index: 1
Last. George Coukos (Ludwig Institute for Cancer Research)H-Index: 93
view all 27 authors...
Summary We investigated the role of chemokines in regulating T cell accumulation in solid tumors. CCL5 and CXCL9 overexpression was associated with CD8 + T cell infiltration in solid tumors. T cell infiltration required tumor cell-derived CCL5 and was amplified by IFN-γ-inducible, myeloid cell-secreted CXCL9. CCL5 and CXCL9 coexpression revealed immunoreactive tumors with prolonged survival and response to checkpoint blockade. Loss of CCL5 expression in human tumors was associated with epigeneti...
127 CitationsSource
#1Mark A. Eckert (U of C: University of Chicago)H-Index: 59
#2Fabian Coscia (UCPH: University of Copenhagen)H-Index: 10
Last. Ernst Lengyel (U of C: University of Chicago)H-Index: 67
view all 20 authors...
High-grade serous carcinoma has a poor prognosis, owing primarily to its early dissemination throughout the abdominal cavity. Genomic and proteomic approaches have provided snapshots of the proteogenomics of ovarian cancer1,2, but a systematic examination of both the tumour and stromal compartments is critical in understanding ovarian cancer metastasis. Here we develop a label-free proteomic workflow to analyse as few as 5,000 formalin-fixed, paraffin-embedded cells microdissected from each comp...
112 CitationsSource
#1Michael R. Savona (Vandy: Vanderbilt University)H-Index: 32
#2Olatoyosi Odenike (U of C: University of Chicago)H-Index: 33
Last. Guillermo Garcia-Manero (University of Texas MD Anderson Cancer Center)H-Index: 122
view all 13 authors...
Summary Background Decitabine, a DNA methyltransferase 1 inhibitor or DNA hypomethylating compound, is not readily orally bioavailable because of rapid clearance by cytidine deaminase (CDA) in the gut and liver. This dose-escalation study, guided by pharmacokinetic and pharmacodynamic observations, evaluated whether simultaneous oral administration with the novel CDA inhibitor cedazuridine increases decitabine bioavailability for the treatment of myelodysplastic syndromes. Methods In this phase ...
44 CitationsSource
Cited By9
#1Sandra Muñoz-Galván (CSIC: Spanish National Research Council)H-Index: 14
#2Amancio Carnero (CSIC: Spanish National Research Council)H-Index: 51
Ovarian cancer is a major cause of fatality due to a gynecological malignancy. This lethality is largely due to the unspecific clinical manifestations of ovarian cancer, which lead to late detection and to high resistance to conventional therapies based on platinum. In recent years, we have advanced our understanding of the mechanisms provoking tumor relapse, and the advent of so-called omics technologies has provided exceptional tools to evaluate molecular mechanisms leading to therapy resistan...
#1Qipeng Fan (IU: Indiana University)H-Index: 4
#2Lihong Li (Johns Hopkins University)
Last. Yan Xu (IU: Indiana University)H-Index: 50
view all 5 authors...
We have recently identified ZIP4 as a novel cancer stem cell (CSC) marker in high-grade serous ovarian cancer (HGSOC). While it converts drug-resistance to cisplatin (CDDP), we unexpectedly found that ZIP4 induced sensitization of HGSOC cells to histone deacetylase inhibitors (HDACis). Mechanistically, ZIP4 selectively upregulated HDAC IIa HDACs, with little or no effect on HDACs in other classes. HDAC4 knockdown (KD) and LMK-235 inhibited spheroid formation in vitro and tumorigenesis in vivo, w...
#1Shatavisha Dasgupta (EUR: Erasmus University Rotterdam)H-Index: 5
#2Patricia C. Ewing-Graham (EUR: Erasmus University Rotterdam)H-Index: 8
Last. Senada Koljenović (EUR: Erasmus University Rotterdam)H-Index: 19
view all 11 authors...
DNA methylation is the most widely studied mechanism of epigenetic modification, which can influence gene expression without alterations in DNA sequences. Aberrations in DNA methylation are known to play a role in carcinogenesis, and methylation profiling has enabled the identification of biomarkers of potential clinical interest for several cancers. For vulvar squamous cell carcinoma (VSCC), however, methylation profiling remains an under-studied area. We sought to identify differentially methy...
#1Jiacheng Shen (Tongji University)
#2Tingwei Liu (Tongji University)
Last. Shaohua Xu (Tongji University)
view all 4 authors...
Epithelial ovarian cancer has a low response rate to immunotherapy and a complex immune microenvironment that regulates its treatment outcomes. Understanding the immune microenvironment and its molecular basis is of great clinical significance in the effort to improve immunotherapy response and outcomes. To determine the characteristics of the immune microenvironment in ovarian cancer, we stratified ovarian cancer patients into three immune subtypes (C1, C2, and C3) using immune-related genes ba...
#2Michelle BilbaoH-Index: 1
Last. Olga OstrovskyH-Index: 3
view all 4 authors...
#1Li-yuan Feng (Guangxi Medical University)H-Index: 1
#2Yong-Zhi Huang (Guangxi Medical University)
Last. Li Li (Guangxi Medical University)H-Index: 34
view all 4 authors...
OBJECTIVE LAMA3 is a widely studied methylated gene in multiple tumors, but the relationship between chemotherapy resistance in ovarian cancer is unclear. In this study, LAMA3 methylation was predicted by bioinformatics, and the ability of LAMA3 methylation to predict the chemotherapy resistance and prognosis of ovarian cancer was confirmed in experiments. METHODS Multiple databases have performed the bioinformatics analysis of methylation and transcription factor binding site (TFBS) on the prom...
#1Kenneth P. Nephew (IU: Indiana University)H-Index: 70
#1Kenneth P. Nephew (IU: Indiana University)H-Index: 10
Last. Kenneth P. Nephew (IU: Indiana University)H-Index: 10
view all 1 authors...
The study by Gonda and colleagues, in this issue of Cancer Research, represents the first combinatorial approach based on epigenetic therapy priming to overcome resistance to immunotherapy in pancreatic cancer. The authors show that treatment with a DNA hypomethylating agent causes profound changes in the pancreatic cancer microenvironment, including increased numbers of tumor-infiltrating T cells, elevated IFN signaling, and immune checkpoint expression, as well as increased antigen presentatio...
1 CitationsSource
#1Shruthi Sriramkumar (IU: Indiana University)H-Index: 3
#2Timothy D. Matthews (IU: Indiana University)H-Index: 1
Last. Heather M. O'Hagan (IU: Indiana University)H-Index: 16
view all 9 authors...
Platinum resistance is a common occurrence in high-grade serous ovarian cancer and a major cause of ovarian cancer deaths. Platinum agents form DNA cross-links, which activate nucleotide excision repair (NER), Fanconi anemia, and homologous recombination repair (HRR) pathways. Chromatin modifications occur in the vicinity of DNA damage and play an integral role in the DNA damage response (DDR). Chromatin modifiers, including polycomb repressive complex 1 (PRC1) members, and chromatin structure a...
3 CitationsSource